Ceryx Medical

Key People

• Dr. Stuart Plant - CEO
  Email: info@ceryxmedical.com
• Professor Alain Nogaret - Co-Founder
• Professor Julian Paton - Co-Founder
• Chas Taylor - Chairman

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in MedTech and healthcare.

Dr. Stuart Plant, CEO, has experience with GE Healthcare and IP Group, focusing on emerging technologies. Co-founders Professors Alain Nogaret and Julian Paton bring extensive research expertise. Chairman Chas Taylor has led multiple cardiovascular businesses, raising over 100m in capital. This collective experience positions Ceryx Medical strongly in the MedTech sector.

Clinical Need

Aspect: Very Strong
Summary: Heart failure affects millions globally, with high mortality rates and limited effective treatments.

Heart failure impacts approximately 30 million people worldwide, with 50% mortality within five years of diagnosis. Current treatments often fail to halt disease progression. Ceryx Medical's Cysoni device aims to restore cardiac performance by synchronizing heartbeats with the respiratory cycle, potentially improving patient outcomes and quality of life.

Competition

Aspect: Somewhat crowded
Summary: The cardiac device market includes established players, but Ceryx's technology offers unique advantages.

The cardiac rhythm management market features major companies like Medtronic and Boston Scientific. However, Ceryx's Cysoni device differentiates itself by mimicking natural heart-lung interactions, potentially offering superior therapeutic benefits over traditional pacemakers.

Technical Challenge

Aspect: Moderate
Summary: Developing bioelectronic devices that integrate seamlessly with human physiology presents moderate challenges.

Creating devices like Cysoni involves replicating biological systems using analog electronics to interpret and respond to physiological signals in real-time. While challenging, Ceryx's preclinical studies have shown promising results, indicating manageable technical hurdles.

Patent

Aspect: Strong
Summary: Ceryx Medical holds unique, patent-protected chip technology for bioelectronic devices.

The company's proprietary technology mimics nerve centers within the body, enabling control over autonomic processes. This intellectual property forms the foundation for their innovative medical devices, providing a barrier to entry for competitors.

Financing

Aspect: Well-funded
Summary: Ceryx Medical has secured significant funding from reputable investors to advance its technology.

The company raised 3.8 million in seed funding in 2022 and an additional 5 million in 2025, totaling approximately $15 million. Investors include the Development Bank of Wales, Parkwalk Advisors, BGF, and Icehouse Ventures. This financial backing enables progression through clinical evaluations and product development.

Regulatory

Aspect: Running FIH
Summary: Ceryx Medical is conducting first-in-human clinical studies for its Cysoni device.

The company commenced first-in-human trials in 2023, following successful preclinical studies. These trials are crucial for obtaining regulatory approvals and demonstrating the device's safety and efficacy in patients.

Opportunity Rollup

Odds of Success

3.9

Peak Market Share

4.8

Segment CAGR

9.1%

Market Segment

Cardiac Rhythm Management Devices

Market Sub Segment

Bioelectronic Pacemakers

Key Takeaway

Ceryx Medical's innovative bioelectronic pacemaker technology addresses a significant unmet need in heart failure treatment, supported by a strong team and substantial funding, positioning the company for potential success in a growing market.